NCT00122616View on ClinicalTrials.gov

Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
HIV InfectionsHepatitis C, Chronic
Interventions
BIOLOGICAL

Peginterferon alpha-2a (Pegasys®)

Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly

DRUG

Ribavirin

Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily

DRUG

HIV antiretroviral therapy

All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs

DRUG

HIV antiretroviral therapy

All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs

Trial Locations (1)

35033

Service de Maladies Infectieuses et de Réanimation Médicale, Rennes

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

French National Agency for Research on AIDS and Viral Hepatitis

OTHER_GOV

NCT00122616 - Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C | Biotech Hunter | Biotech Hunter